| Acetylcysteine Rinse in Reducing Saliva Thickness and Mucositis in Patients With Head and Neck Cancer Undergoing Radiation Therapy (NCT02123511) | Mayo Clinic | 2014-04-01 |
| Talactoferrin in Treating Patients With Relapsed or Refractory Non-Small Cell Lung Cancer or Squamous Cell Head and Neck Cancer (NCT01528137) | Stanford University | 2012-05-01 |
| Phase I Study of IMRT and Molecular-Image Guided Adaptive Radiation Therapy for Advanced HNSCC (NCT01283178) | Virginia Commonwealth University | 2011-07-01 |
| TLR8 Agonist VTX-2337 and Cetuximab in Treating Patients With Locally Advanced, Recurrent, or Metastatic Squamous Cell Cancer of Head and Neck (NCT01334177) | University of Washington | 2011-06-01 |
| L-lysine in Treating Oral Mucositis in Patients Undergoing Radiation Therapy With or Without Chemotherapy For Head and Neck Cancer (NCT01155609) | University of Washington | 2010-09-01 |
| Sunitinib, Cetuximab, and Radiation Therapy in Treating Patients With Locally Advanced or Recurrent Squamous Cell Carcinoma of the Head and Neck (NCT00906360) | National Cancer Institute (NCI) | 2008-07-01 |
| Phase 1b Food Based Modulation of Biomarkers in Human Tissues at High-Risk for Oral Cancer. (NCT01469429) | Ohio State University Comprehensive Cancer Center | 2007-09-04 |
| Bevacizumab in Reducing CNS Side Effects in Patients Who Have Undergone Radiation Therapy to the Brain for Primary Brain Tumor, Meningioma, or Head and Neck Cancer (NCT00492089) | National Cancer Institute (NCI) | 2007-06-01 |
| Erlotinib and Cetuximab With or Without Bevacizumab in Treating Patients With Metastatic or Unresectable Kidney, Colorectal, Head and Neck, Pancreatic, or Non-Small Cell Lung Cancer (NCT00101348) | National Cancer Institute (NCI) | 2005-01-01 |
| Bortezomib Followed by the Addition of Doxorubicin at Disease Progression in Treating Patients With Locally Advanced, Recurrent, or Metastatic Adenoid Cystic Carcinoma (Cancer) of the Head and Neck (NCT00077428) | National Cancer Institute (NCI) | 2004-06-01 |
| Intratumoral PV701 in Treating Patients With Advanced or Recurrent Unresectable Squamous Cell Carcinoma of the Head and Neck (NCT00081211) | National Cancer Institute (NCI) | 2004-04-01 |
| Gefitinib in Treating Patients With Metastatic or Unresectable Head and Neck Cancer or Non-Small Cell Lung Cancer (NCT00068497) | National Cancer Institute (NCI) | 2003-08-01 |
| Vaccine Therapy With or Without Sargramostim in Treating Patients With Advanced or Metastatic Cancer (NCT00028496) | National Cancer Institute (NCI) | 2001-11-01 |
| Bevacizumab, Fluorouracil, and Hydroxyurea Plus Radiation Therapy in Treating Patients With Advanced Head and Neck Cancer (NCT00023959) | National Cancer Institute (NCI) | 2001-07-01 |
| Interleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of HER2/Neu (NCT00004074) | National Cancer Institute (NCI) | 1999-08-01 |